Insulet stock falls 1.13 percent as guidance concerns persist

Published on 09/29/2026 at 16:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Insulet stock delivered USD 801.70 million in Q2 2026 revenue, up 23.50 percent year over year. Full-year growth guidance is 20.00 to 22.00 percent after type 2 retention issues.

Reinraum-Fertigung Insulet – Medizintechnik-Mitarbeiter montieren Insulinpumpen-Pods an Edelstahlbänken — Insulet Reinraum in der Medizintechnik: Mitarbeiter montieren schlauchfreie Insulin-Pods an Edelstahlbänken, ISIN US45784P1012, Illustration mit AI erstellt.

Insulet stock (ISIN US45784P1012) was trading at EUR 115.73 at Lang & Schwarz on September 29, 2026 at 4:34 p.m. CEST, down 1.13 percent versus the prior close of EUR 117.05. TrustFinance reported on September 28, 2026, that the shares were extending their decline as investors assessed the companys reduced outlook and softer type 2 customer retention.

Revenue growth stays strong

Insulet generated USD 801.70 million in second-quarter 2026 revenue, up 23.50 percent from the prior-year quarter. According to The Globe and Mail on August 5, 2026, adjusted EPS rose 41.50 percent year over year to USD 1.66 from USD 1.17.

The earnings profile therefore remained stronger than the share-price reaction. Adjusted operating margin reached 19.30 percent in Q2 2026, an increase of 1.40 percentage points, while international Omnipod revenue growth reached 32.90 percent on a constant-currency basis.

Type 2 retention changes guidance

Management now expects 2026 total-company revenue growth of 20.00 to 22.00 percent, while U.S. Omnipod growth is guided to 17.00 to 19.00 percent. The prior U.S. range was 20.00 to 22.00 percent, making retention and utilization among type 2 customers the central execution issue.

The international outlook moved in the opposite direction. Insulet raised international Omnipod growth guidance to 30.00 to 32.00 percent from 26.00 to 28.00 percent, according to the August 5, 2026 earnings call. That split gives the stock a clear tension between strong international demand and weaker U.S. execution.

Analyst targets remain divided

MarketBeat reported on September 5, 2026, that 27 analysts held a consensus Hold rating with an average 12-month price target of USD 195.40. The report also said RBC reduced its target from USD 245.00 to USD 160.00, showing how the guidance reset has affected valuation assumptions.

Insulet stock trades below prior close

Insulet stock was trading at EUR 115.73 at Lang & Schwarz on September 29, 2026 at 4:34 p.m. CEST, down 1.13 percent against the prior close of EUR 117.05. The company had a market capitalization of USD 9.1 billion and a 52-week range of USD 126.40 to USD 354.88 as of September 29, 2026.